



Drug Name: Verzenio (abemaciclib)
Date: 9-2018

Drug Name: Verzenio	
Required Medical Information:	<ul style="list-style-type: none"> • Prescriber is an oncologist • Drug is being used for a medically-accepted indication (approved by the FDA or compendia-supported) <ul style="list-style-type: none"> ○ Diagnosis of advanced or metastatic breast cancer ○ Hormone receptor (HR)-positive breast cancer ○ Human epidermal growth factor receptor 2 (HER2)-negative breast cancer ○ Documentation of use: initial endocrine therapy, progression following endocrine therapy, or monotherapy <ul style="list-style-type: none"> ▪ If initial endocrine therapy: member is postmenopausal and drug will be used in combination with an aromatase inhibitor ▪ If progression following endocrine therapy: drug will be used in combination with fulvestrant ▪ If monotherapy: documentation of disease progression following endocrine therapy and at least one prior chemotherapy in the metastatic setting
Quantity Limit:	60 tablets per 30 days (First fill will be limited up to a 15 day supply, if possible)
Coverage	12 months
Duration:	